Caribou Biosciences, Inc. (CRBU)
1.615
-0.04
(-2.71%)
USD |
NASDAQ |
Aug 28, 16:00
1.615
0.00 (0.00%)
After-Hours: 19:07
Caribou Biosciences Debt to Equity Ratio : 0.2717 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.2717 |
| March 31, 2026 | 0.2641 |
| December 31, 2025 | 0.2229 |
| September 30, 2025 | 0.1795 |
| June 30, 2025 | 0.1556 |
| March 31, 2025 | 0.1207 |
| December 31, 2024 | 0.1048 |
| September 30, 2024 | 0.0948 |
| June 30, 2024 | 0.088 |
| March 31, 2024 | 0.0804 |
| December 31, 2023 | 0.0746 |
| September 30, 2023 | 0.0689 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.1011 |
| March 31, 2023 | 0.0985 |
| December 31, 2022 | 0.0922 |
| September 30, 2022 | 0.086 |
| June 30, 2022 | 0.0804 |
| March 31, 2022 | 0.0755 |
| December 31, 2021 | 0.0007 |
| September 30, 2021 | 0.0022 |
| June 30, 2021 | -3.160 |
| March 31, 2021 | -4.267 |
| December 31, 2020 | -1.839 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Intellia Therapeutics, Inc. | 0.1009 |
| Vir Biotechnology, Inc. | 0.0949 |
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 142.77M |
| Total Liabilities (Quarterly) | 44.67M |
| Shareholders Equity (Quarterly) | 98.10M |
| Current Ratio | 6.487 |
| Net Debt Paydown Yield | -0.05% |